Search, analyze & compare

Company details

Achilles Therapeutics plc - ADR represents an innovative biopharmaceutical company that develops precision T cell therapies targeting clonal neoantigens, which are proteins specific to cancer cells. The primary purpose of Achilles Therapeutics is to revolutionize cancer treatment by harnessing the body's immune system to selectively target and destroy cancer cells, thereby offering more targeted therapeutic options with potentially fewer side effects compared to traditional methods. The company primarily focuses on treatment options for solid tumors, contributing to advancements in industries related to oncology and immunotherapy. Achilles Therapeutics’ operations hold significant importance as they address unmet medical needs in the global healthcare market. By leveraging advanced genetic and bioinformatics technologies, the firm aims to offer personalized medicine solutions, which are increasingly becoming crucial in the fight against cancer. As an American Depositary Receipt (ADR), Achilles Therapeutics plc provides U.S. investors the ability to invest in its shares, facilitating broader access to their innovative therapeutic developments beyond the UK market where it is primarily based. This role in the market underscores its commitment to bring cutting-edge cancer therapies worldwide, aligning with the growing demand for precision medicine.